Skip to main
KURA

Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology (KURA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kura Oncology Inc. demonstrates a positive outlook due to its promising pipeline, particularly with KO-2806's ability to enhance the efficacy of cabozantinib in treating resistant solid tumors, signaling innovative advancements in cancer therapies. The early commercial success of KOMZIFTI indicates robust market potential and anticipated growth momentum that could extend into 2026. Additionally, the company's strong cash position provides the necessary resources and flexibility to effectively advance its clinical and commercial objectives, reinforcing confidence in its future performance.

Bears say

Kura Oncology faces significant risks that could adversely affect its stock performance, primarily stemming from the potential failure or delay in the approval of key drug candidates such as ziftomenib and tipifarnib. The company's product pipeline may encounter setbacks, including inconclusive clinical trial results or safety issues that could impede development and diminish market competitiveness against emerging therapies. Additionally, financial challenges related to securing sufficient funding further exacerbate the risk profile, complicating Kura’s ability to advance its projects through the necessary stages of drug development.

Kura Oncology (KURA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kura Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kura Oncology (KURA) Forecast

Analysts have given Kura Oncology (KURA) a Buy based on their latest research and market trends.

According to 8 analysts, Kura Oncology (KURA) has a Buy consensus rating as of Apr 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kura Oncology (KURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.